Territorial Availability: Available through Bertin Technologies only in France
- Correlated keywords
- PhosphoThr288 PhosphoThr232 PhosphoThr198 Thr 232 198 RM 454 AMG900 HCT 116
- Product Overview:
The Aurora kinases, Aurora A, -B, and -C, are a family of serine/threonine kinases encoded by distinct genes, AURKA, AURKB, and AURKC, respectively, that have roles in mitosis and meiosis.{64176,64177} They are composed of an ATP-binding N-terminal domain, a highly conservated catalytic domain, and a short C-terminal domain that contains an activation loop and mediates cofactor binding.{64176} Each Aurora kinase contains a key threonine residue in its C-terminal activation loop, threonine 288 (Thr288), Thr232, and Thr198 in Aurora A, -B, and -C, respectively, that is autophosphorylated upon cofactor binding, inducing a conformational change that mediates kinase activation.{64176,64177} Aurora A and Aurora B have roles in mitosis, whereas Aurora C regulates meiosis.{64177} Aurora A and Aurora B are constitutively expressed in mitotic cells, where Aurora A localizes to the spindle poles and Aurora B localizes to the central spindle.{64177} Aurora A has roles in mitotic entry, centrosome maturation and separation, and spindle assembly, whereas Aurora B regulates chromosome condensation and alignment, spindle assembly, and cytokinesis. Aurora C is expressed in germ cells during meiosis, localizes to the chromosome midbody, and is required for spermatogenesis.{64177,64178} Aurora A, -B, and -C are overexpressed in a variety of cancers, including breast, colorectal, ovarian, and cervical cancers, and the pan-Aurora kinase inhibitor AMG 900 (Item No. 19176) inhibits tumor growth in an HCT116 mouse xenograft model.{64178,31008} Cayman’s Aurora A (Phospho-Thr288)/Aurora B (Phospho-Thr232)/Aurora C (Phospho-Thr198) Rabbit Monoclonal Antibody can be used for immunohistochemistry (IHC) and Western blot (WB) applications.
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.